Spinout Active LTD

Company profile

Imperagen Limited

UK company 13761050, incorporated on 23 November 2021.

Imperagen Ultrafast Enzyme Engineering

Imperagen Limited is a UK company with status Active founded in 2021.

Company number
13761050
Incorporated
23 Nov 2021
Companies House status
Active

Company identity

Browse spinouts
Founded / incorporated
23 November 2021

Company number 13761050

Verify at Companies House
Legal name
IMPERAGEN LIMITED
Company type
Private Limited Company
Region
Unknown
Registered address
UNIT 11, WILLIAMS HOUSE LLOYD STREET NORTH
MANCHESTER SCIENCE PARK
MANCHESTER
ENGLAND
M15 6SE
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

5 events
30 Sep
2027

Accounts due

Accounts Due

Next accounts due date

20 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

06 Dec
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

23 Nov
2021

Incorporated

Inception

Company registered at Companies House

Spinout profile

4 entries

Company description

Imperagen develops technology to accelerate the development of enzyme biocatalysts for use in drug discovery.

TBA

Project impact

n/a

This company has just set up labs in Manchester science park with major investment to recruit and develop the expert team.

Imperagen
2021
Imperagen
2021
Imperagen
2021
IMPERAGEN LIMITED
2021

Public funding

2 awards
First funded
2023
Funded years
2023, 2024
Age at first award
1 years

Projects

2024 Collaborative R&D Lead participant

Accelerated, multi-parameter enzyme optimisation for the process scale-up of a novel pharmaceutical biocatalyst

1 Feb 2024 to 31 Jan 2025

Awarded
£244,539
Total cost £349,342

There is a global urgency to address the climate emergency and environmental disaster from unsustainable industrial activity. Chemical manufacturing depends on highly polluting petrochemical-based processes that **use** substantial energy, produce toxic waste and are dependent on geopolitically fragile mining for increasingly scarce metallic catalysts. Ch...

2023 Collaborative R&D Lead participant

Imperagen, developing a breakthrough technology needed to bring ultra-fast enzyme engineering to market

1 Jul 2023 to 30 Jun 2024

Awarded
£291,481
Total cost £291,481

There is a global urgency to address the climate emergency and the environmental disaster from unsustainable industrial activity. Chemical manufacturing depends on highly polluting petrochemical-based processes that use substantial energy, produce toxic waste and dependant on increasingly scarce metallic catalysts. Chemical modification of compounds that ...

Product types

Collaborative R&D